Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size to Grow at a CAGR of 43.7% Between 2022-2027

The ‘Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Report and Forecast 2022-2027’ by Expert Market Research gives an extensive outlook of the global non-alcoholic steatohepatitis (NASH) treatment market, assessing the market on the basis of its segments like drug types, disease causes, end-uses, and major regions.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Trends, Industry Report, Key Player, Major Segments, and Forecast

Get a Free Sample Report with Table of Contents – https://www.expertmarketresearch.com/reports/non-alcoholic-steatohepatitis-nash-treatment-market/requestsample

The key highlights of the report include:

Market Overview (2017-2027)

• Forecast CAGR (2022-2027): 43.7%

Report Attribute	Details
Historical Period	2017-2021
Forecast Period	2022-2027
Base Year	2021
Growth Rate CAGR	43.7%
Major Players	Zydus Cadila, Novartis AG, Pfizer Inc., Madrigal Pharmaceuticals, InterceptPharmaceuticals, and Genfit SA, among others.

Non-alcoholic steatohepatitis (NASH) treatment is gaining traction across the healthcare units to counter advanced liver diseases. The rising prevalence of obesity, diabetes mellitus, and high cholesterol is leading to an increasing demand for non-alcoholic steatohepatitis (NASH) treatment drugs and products. The unhealthy lifestyles led by the working-class population, which is resulting in an unbalanced intake of calories, is further bolstering the global non-alcoholic steatohepatitis (NASH) treatment market.

According to a report by World Health Organisation, around 422 million people suffer from diabetes around the world. This figure is estimated to increase in the coming years. Meanwhile, approximately 300 million people around the world are asthmatic. Over the forecast period, this alarming rate of chronic illnesses may lead to heightened cases of NASH.

Moreover, the rising geriatric population, coupled with the chances of liver failure associated with it, is a major driving factor of the market. Non-alcoholic steatohepatitis (NASH) treatment reduces the need for liver transplant, which is a lengthy and expensive procedure. This advantage of NASH treatment is anticipated to offer opportunities to the global non-alcoholic steatohepatitis (NASH) treatment market in the forecast period.

During the forecast period, Asia Pacific is expected to account for a significant share in the market owing to the presence of large population base across India and China, coupled with the increasing prevalence of diabetes mellitus and NASH.

Meanwhile, North America is anticipated to register a considerable growth in the coming years due to the rising cases of obesity among youngsters and the technologically advanced healthcare infrastructure across the United States of America and Canada.

Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Definition and Major Segments

Non-alcoholic steatohepatitis (NASH) refers to a type of fatty liver disease which is caused by excess of fat in the liver. This disease causes damage to the liver. Non-alcoholic steatohepatitis (NASH) treatment aims at providing comfort to the victims of this disease using medications or equipment. Increasing prevalence of NASH is driving the demand for non-alcoholic steatohepatitis (NASH) treatment market.

Read Full Report With Table Of Content- https://www.expertmarketresearch.com/reports/non-alcoholic-steatohepatitis-nash-treatment-market

Based on drug type, the market can be segmented into:

• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib and Cencicriviroc
• Others

The market can be broadly categorised based on disease cause into:

• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 diabetes
• Obesity
• Others

The significant end-uses included in the non-alcoholic steatohepatitis (NASH) treatment market are as follows:

• Hospitals
• Clinics
• Homecare Settings

On the basis of region, the market can be categorised into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends

The key factors in the global non-alcoholic steatohepatitis (NASH) treatment market include the rising healthcare expenditure and technological advancements across the healthcare units in the emerging economies. The aim of these advancements is to bolster the diagnosis process of NASH and to spearhead the quality of treatment procedure.

The increasing incorporation of high-tech artificial intelligence devices in the MRI and ultrasound procedures are likely to aid the market growth, supported by the rapid advancements in healthcare infrastructure.

The growing research and development activities by the major market players to boost the efficiency of treatment procedures are the major trends in the market. Further, increasing initiatives for the awareness of NASH and the growing number of clinical trials involving combination studies of drugs are propelling the market growth.

Key Market Players

Some major players in the market:

• Zydus Cadila
• Novartis AG
• Pfizer Inc
• Madrigal Pharmaceuticals
• Intercept Pharmaceuticals
• Genfit SA
• Others

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.